PMID- 29312741
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 9
IP  - 12
DP  - 2017 Dec
TI  - Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors 
      in resectable non-small cell lung cancer: an updated meta-analysis.
PG  - 5314-5321
LID - 10.21037/jtd.2017.12.58 [doi]
AB  - BACKGROUND: A previous meta-analysis of our research team suggested survival 
      advantage from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
      (TKIs) after surgery in patients with EGFR-mutant non-small cell lung cancer 
      (NSCLC). This study aims to follow up on the findings of the previous one and 
      presents our latest updates through the past few years. METHODS: The study 
      advanced the previous meta-analysis and included a comprehensive range of 
      relevant studies in PubMed. Disease-free survival (DFS) with hazard ratios (HRs) 
      was calculated using random and/or fixed-effects models. Subgroup analysis and 
      meta-regression analysis were also performed. RESULTS: A total of 2,223 patients 
      in seven studies were eligible for the analysis. Adjuvant EGFR-TKIs 
      administration was significantly associated with superior DFS [HR, 0.60; 95% 
      confidence interval (CI), 0.42-0.87], corresponding to an absolute benefit of 
      3.4% at 3 years, yet with significant heterogeneity (I(2)=80.0%, P <0.001). EGFR 
      mutation rate of included patients was found to be a source of heterogeneity by 
      meta-regression analysis (P=0.005). In the EGFR-mutant sub-population, HR for DFS 
      was 0.51 (95% CI, 0.39-0.65), corresponding to an absolute benefit of 7.1% at 3 
      years. The rate of overall grade 3 or greater adverse events (AEs) was 38.9% (95% 
      CI, 35.9-41.9%). CONCLUSIONS: The updated meta-analysis provided strengthened 
      evidence of significant DFS advantage of adjuvant EGFR-TKI treatment for patients 
      with EGFR-mutant NSCLC after complete resection.
FAU - Yuan, Yonggang
AU  - Yuan Y
AD  - Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong 
      University, Shanghai 200030, China.
AD  - Department of Thoracic Surgery, Yidu Central Hospital of Weifang, Weifang 262500, 
      China.
FAU - Huang, Qingyuan
AU  - Huang Q
AD  - Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong 
      University, Shanghai 200030, China.
AD  - Perlmutter Cancer Center, New York University, New York, NY, USA.
FAU - Gu, Chang
AU  - Gu C
AD  - Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong 
      University, Shanghai 200030, China.
FAU - Chen, Haiquan
AU  - Chen H
AD  - Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong 
      University, Shanghai 200030, China.
AD  - Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai 
      200032, China.
AD  - Shanghai Medical College, Fudan University, Shanghai 200032, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC5757008
OTO - NOTNLM
OT  - Epidermal growth factor receptor (EGFR)
OT  - adjuvant treatment
OT  - lung cancer
OT  - survival
OT  - tyrosine kinase inhibitor (TKI)
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:01
PMCR- 2017/12/01
CRDT- 2018/01/10 06:00
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:01 [medline]
PHST- 2017/12/01 00:00 [pmc-release]
AID - jtd-09-12-5314 [pii]
AID - 10.21037/jtd.2017.12.58 [doi]
PST - ppublish
SO  - J Thorac Dis. 2017 Dec;9(12):5314-5321. doi: 10.21037/jtd.2017.12.58.